1. Home
  2. TNGX vs NCZ Comparison

TNGX vs NCZ Comparison

Compare TNGX & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$8.86

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Virtus Convertible & Income Fund II of Beneficial Interest

NCZ

Virtus Convertible & Income Fund II of Beneficial Interest

HOLD

Current Price

$13.83

Market Cap

265.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNGX
NCZ
Founded
2014
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
265.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNGX
NCZ
Price
$8.86
$13.83
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$12.50
N/A
AVG Volume (30 Days)
2.6M
533.0K
Earning Date
11-04-2025
01-01-0001
Dividend Yield
N/A
12.16%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,501,000.00
N/A
Revenue This Year
$52.80
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.29
N/A
52 Week Low
$1.03
$2.50
52 Week High
$11.20
$3.15

Technical Indicators

Market Signals
Indicator
TNGX
NCZ
Relative Strength Index (RSI) 49.33 47.01
Support Level $8.45 $13.92
Resistance Level $9.00 $14.15
Average True Range (ATR) 0.52 0.19
MACD -0.06 0.01
Stochastic Oscillator 31.74 46.56

Price Performance

Historical Comparison
TNGX
NCZ

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About NCZ Virtus Convertible & Income Fund II of Beneficial Interest

Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.

Share on Social Networks: